Barings’s DexCom DXCM Stock Holding History

Barings’s Portfolio DXCM Stock Details DXCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-1,848	Closed	-$252K	–	378
2021 Q3	$252K	Buy	+1,848	New	+$233K	0.01%	347
2020 Q4	–	Sell	-6,684	Closed	-$689K	–	473
2020 Q3	$689K	Buy	+6,684	New	+$698K	0.02%	388

Other funds holding DXCM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Barings's DXCM Position: Q4 2021 in Review

Barings sold out of DexCom (DXCM) in Q4 2021, closing a stake of 1,848 shares — an estimated $252K sold.

Barings first reported a position in DXCM in Q3 2020 and held it in 2 quarters. The position peaked at $689K in Q3 2020. 930 funds tracked by Wall St. Rank hold DXCM as of Q4 2021.

Barings reported no remaining DexCom position as of Q4 2021 after selling out during the quarter.
Barings sold 1,848 DexCom shares in Q4 2021, an estimated $252K.
Barings first reported a position in DexCom in Q3 2020 and held it in 2 quarters.
Barings's DexCom position peaked at $689K in Q3 2020.
930 funds tracked by Wall St. Rank held DexCom as of Q4 2021.

Based on Barings's 13F filing for Q4 2021, filed 9 Feb 2022.